Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes an identifiable offering with both: (1) customer response running ahead of what company prepared for, and (2) company responding now by putting more behind it. The offering must be small relative to total business. Scan transcript for such descriptions. Key candidates: 60% protein, clean sugar (dextrose), carbon capture, etc. Look for language about demand exceeding preparation, and concrete steps to expand. For 60% protein: Todd says "we have enough identified demand that could take all of our product" but that's not current uptake, it's potential. Also "we are in enough negotiations" - that's pipeline, not actual orders. He says "we have sold some 60% protein commercially in smaller beginning quantities" - that's current but small. But is there a gap between customer response and preparation? He says "we have enough identified demand" but that's not necessarily running ahead of preparation. Also "we are in the process of finishing some commercial feed trials" - not yet. So not clearly ahead. For clean sugar: "we will be ready to begin delivering product in the beginning of the second quarter" - future. "we continue to have strong interest" - interest, not orders. "late-stage negotiations" - not yet. So no current uptake. For carbon capture: not an offering to customers, it's a project. What about renewable corn oil? "Our renewable corn oil production saw another impressive quarter with the highest yield" - that's production, not customer response. Maybe the Tharaldson JV? Not described as demand ahead. Look for phrases like "demand is exceeding" or "we can't keep up" or "we are expanding capacity because of demand." I don't see that. Management does mention "we have enough identified demand to take all of our product" for 60 pro, but that's not current uptake, it's potential. Also they say "we are in enough negotiations" - that's not actual orders. Also they say "we have sold some 60% protein commercially" - but that's small, and they are not describing that it's ahead of preparation. They are preparing to sell more, but not because of a surge. Thus, no clear evidence of both halves. Answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).